ALGN Align Technology, Inc. - Fundamental Analysis
NEUTRAL
Sign in to save
Save this symbol to a watchlist or track a position.
ALGN Stock | Fundamental Analysis & Investment Insights
NASDAQ
Healthcare
Medical Instruments & Supplies
Current Price
Live
$164.23
Analyst Target
$201.57
+22.7%
Upside
52W High
$208.31
52W Low
$122.0
At a glance
Key valuation, profitability, growth, and risk metrics.
Updated Mar 14, 2026
Market cap
$11.78B
P/E
29.07
ROE
10.4%
Profit margin
10.2%
Debt/Equity
0.03
Dividend yield
N/A
AI Analysis
Powered by advanced machine learning algorithms
Confidence Score
78%
Analysis Accuracy
ALGN's Piotroski F-Score of 4/9 indicates weak financial health, signaling potential operational inefficiencies despite stable profitability. The absence of an Altman Z-Score raises concern about default risk, though the company's extremely low debt/equity ratio (0.03) and strong liquidity support financial stability. The stock trades near its intrinsic value of $166.68 but at a premium to the Graham Number ($84.93), reflecting high growth expectations. Analysts maintain a 'buy' consensus with a target price of $201.57, suggesting upside, though recent insider selling and inconsistent earnings surprises temper enthusiasm.
Key Strengths
Strong gross margin of 69.80% indicates pricing power and efficient production
Low debt/equity ratio (0.03) reflects conservative capital structure and strong financial health
High operating margin (22.38%) and solid ROE (10.39%) demonstrate effective cost management and profitability
Significant earnings growth (35.6% YoY) and strong Q/Q EPS growth (+321.8%) signal robust top-line momentum
Analyst consensus remains bullish with a $201.57 target, implying 22.7% upside from current price
Key Risks
Piotroski F-Score of 4/9 is below the threshold for strong financial health, indicating potential red flags in operational efficiency or capital allocation
Recent insider selling (1 transaction, $1.51M) suggests possible lack of confidence among executives
Earnings surprise history shows inconsistency, with recent misses (e.g., -39.3% in Q3 2025) and volatility in performance
Current price ($164.23) is nearly double the Graham Number ($84.93), indicating high valuation relative to conservative intrinsic value
52-week high is $208.31, and the stock has declined 70.6% over 5 years, reflecting long-term underperformance despite recent rebound
AI Fair Value Estimate
Based on comprehensive analysis
$166.68
+1.5% above current price
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Overall
46
Moderate
55
78
52
45
0
AI Verdict
neutral
Key drivers: Strong profitability and low leverage, High growth in earnings and revenue, Weak Piotroski F-Score and inconsistent earnings surprises, High valuation relative to Graham Number
Confidence
75%
Value
55/100
Ref P/E, PEG, Graham Number
Positives
- Intrinsic value estimate of $166.68 aligns closely with current price
- Forward P/E of 13.39 is attractive relative to current P/E of 29.07
Watchpoints
- Current price is 92% above Graham Number ($84.93), indicating significant premium
- Price/Sales of 2.92 is elevated for a healthcare stock
Future
78/100
Ref Growth rates
Positives
- 35.6% YoY earnings growth and 30.8% Q/Q earnings growth show strong momentum
- Forward P/E of 13.39 suggests market expects continued growth
Watchpoints
- PEG ratio not available, limiting growth-adjusted valuation assessment
- Recent earnings misses (e.g., -39.3%) indicate execution risk
Past
52/100
Ref Historical trends
Positives
- Consistent profitability with stable gross and operating margins
- Positive long-term revenue growth trend (5.3% YoY)
Watchpoints
- 5-year price decline of 70.6% reflects poor capital appreciation
- Inconsistent earnings surprises, including multiple negative misses
Health
45/100
Ref Altman Z-Score, Piotroski F-Score
Positives
- Extremely low debt/equity (0.03) and strong current/quick ratios (1.36, 1.17)
- No Altman Z-Score available, but low leverage reduces distress risk
Watchpoints
- Piotroski F-Score of 4/9 is below the stable threshold (4-6), indicating weak financial health
- Lack of positive signals in cash flow and asset turnover may be hidden
Dividend
0/100
Ref Yield, Payout
Positives
No standout positives identified.
Watchpoints
- No dividend paid, payout ratio is 0%
- Dividend yield and rate are not applicable
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Current Price
$164.23
Analyst Target
$201.57
Upside/Downside
+22.7%
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for ALGN and closest competitors.
Updated 2026-03-13
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
ALGN
Align Technology, Inc.
Primary
|
-70.6% | -48.8% | +2.3% | +24.8% | -16.9% | -5.6% |
|
BMRN
BioMarin Pharmaceutical Inc.
Peer
|
-36.8% | -50.6% | -9.6% | -4.7% | -6.6% | +3.0% |
|
MOH
Molina Healthcare, Inc.
Peer
|
-12.6% | -36.1% | -32.3% | +4.6% | +17.9% | +5.5% |
|
NBIX
Neurocrine Biosciences, Inc.
Peer
|
+21.7% | +22.3% | -6.7% | +0.3% | -6.6% | -2.5% |
|
BAX
Baxter International Inc.
Peer
|
-72.4% | -52.4% | -37.8% | -31.6% | +3.8% | -1.3% |
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Historical data shows last 12 quarters (3 years)
Valuation Metrics
Key valuation ratios and pricing indicators
P/E Ratio
29.07
Forward P/E
13.39
PEG Ratio
N/A
P/B Ratio
2.89
P/S Ratio
2.92
EV/Revenue
2.66
EV/EBITDA
12.6
Market Cap
$11.78B
Profitability
Profit margins and return metrics
Profit Margin
10.17%
Operating Margin
22.38%
Gross Margin
69.8%
ROE
10.39%
ROA
6.94%
Growth
Revenue and earnings growth rates
Revenue Growth
+5.3%
Earnings Growth
+35.6%
Q/Q Revenue Growth
N/A
Q/Q Earnings Growth
+30.8%
Financial Health
Balance sheet strength and liquidity metrics
Debt/Equity
0.03
Low debt
Current Ratio
1.36
Good
Quick Ratio
1.17
Good
Cash/Share
$15.36
Quarterly Earnings History
EPS performance vs analyst estimates
2026-04-29
$N/A
2026-02-04
$3.29
+10.8% surprise
2025-10-29
$0.78
-39.3% surprise
2025-07-30
$2.49
-3.3% surprise
Healthcare Sector Comparison
Comparing ALGN against 147 companies in the Healthcare sector
(10 bullish, 55 neutral, 82 bearish)
P/E Ratio
29.07
This Stock
vs
164.56
Sector Avg
-82.3%
(Discount)
Return on Equity (ROE)
10.39%
This Stock
vs
-52.77%
Sector Avg
-119.7%
(Below Avg)
Profit Margin
10.17%
This Stock
vs
-20.78%
Sector Avg
-149.0%
(Weaker)
Debt to Equity
0.03
This Stock
vs
6.16
Sector Avg
-99.5%
(Less Debt)
Revenue Growth
5.3%
This Stock
vs
137.39%
Sector Avg
-96.1%
(Slower)
Current Ratio
1.36
This Stock
vs
3.36
Sector Avg
-59.4%
(Weaker)
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
ALGN
Align Technology, Inc.
|
NEUTRAL | $11.78B | 29.07 | 10.4% | 10.2% | $164.23 | |
|
BMRN
BioMarin Pharmaceutical Inc.
|
NEUTRAL | $10.8B | 21.29 | 9.1% | 16.8% | $56.21 | |
|
MOH
Molina Healthcare, Inc.
|
BEARISH | $10.37B | 11.79 | 19.7% | 2.1% | $191.4 | |
|
NBIX
Neurocrine Biosciences, Inc.
|
NEUTRAL | $13.2B | 31.6 | 15.0% | 16.0% | $132.39 | |
|
BAX
Baxter International Inc.
|
BEARISH | $10.2B | - | -4.7% | -3.1% | $19.84 |
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2026-02-20 | HOGAN JOSEPH M | Chief Executive Officer | Stock Award | 40,248 | - |
| 2026-02-20 | HOCKRIDGE STUART A | Officer | Stock Award | 4,310 | - |
| 2026-02-20 | MORICI JOHN F. | Chief Financial Officer | Stock Award | 7,848 | - |
| 2026-02-20 | COLETTI JULIE ANN | Officer | Stock Award | 5,864 | - |
| 2026-02-18 | MORICI JOHN F. | Chief Financial Officer | Sale | 7,969 | $1,508,646 |
Insider transactions can signal confidence or concerns about company prospects
Wall Street Analysts
Professional analyst ratings and price targets
Consensus
BUY
14 analysts
Barclays
2026-02-26
Equal-Weight
Equal-Weight
HSBC
2026-02-09
Hold
Buy
Stifel
2026-02-05
Buy
Buy
Piper Sandler
2026-02-05
Overweight
Overweight
UBS
2026-02-05
Neutral
Neutral
Evercore ISI Group
2026-02-05
Outperform
Outperform
Wells Fargo
2026-02-05
Overweight
Overweight
Morgan Stanley
2026-02-05
Equal-Weight
Equal-Weight
Mizuho
2026-01-20
Outperform
Outperform
Barclays
2025-12-09
Equal-Weight
Past News Coverage
Recent headlines mentioning ALGN from our newsroom.
Newest → oldest
No matching news yet.